Symptom control and brain protection
›General management principles
›Relative rest for 24 to 48 hours
›Symptom-limited physical activity after initial rest
›Sleep hygiene support
›Regular sleep schedule
›Avoid alcohol and sedatives
›Masking neurologic decline risk
›Avoid second impact until cleared
›Catastrophic brain swelling risk in rare cases
›Analgesia
›Acetaminophen
›Adult dosing
›650 to 1000 mg orally every 6 hours as needed
›Maximum 3000 mg per 24 hours typical conservative ceiling
›Pediatric dosing
›15 mg per kg orally every 6 hours as needed
›Maximum 60 mg per kg per 24 hours typical
›NSAID use considerations
›Avoid in first 24 hours when hemorrhage not excluded
›Preference for acetaminophen early
›If CT negative and no bleeding risk, NSAID reasonable for headache
›Ibuprofen adult dosing
›400 mg orally every 6 hours as needed
›Maximum 1200 mg per 24 hours over the counter typical
›Avoid opioids when possible
›Sedation and symptom confounding
›Antiemetics
›Ondansetron
›Adult dosing
›4 mg orally or IV every 8 hours as needed
›QT prolongation risk consideration
›Pediatric dosing
›0.15 mg per kg orally or IV
›Maximum 8 mg per dose
›Headache phenotype guided therapy
›Migraine-like headache
›Metoclopramide IV
›10 mg IV
›Dystonia prevention with diphenhydramine optional
›Prochlorperazine IV
›10 mg IV
›Akathisia risk monitoring
›Cervicogenic component
›Heat and gentle range of motion
›Early physiotherapy referral when persistent
›Dizziness and vestibular symptoms
›Vestibular rehabilitation referral for persistent symptoms
›Balance therapy improves recovery in selected patients
›Meclizine short course for severe vertigo
›Adult dosing
›25 mg orally every 8 hours as needed
›Sedation risk and avoidance of prolonged use
›Cognitive symptoms and school or work accommodations
›Return-to-learn staged plan
›Initial reduced screen time
›Short study blocks with breaks
›Work restrictions
›No driving if slowed reaction or dizziness
›Anticoagulation and antiplatelet management
›If intracranial hemorrhage present, reversal pathway
›Warfarin
›Vitamin K IV
›10 mg IV
›Slow infusion to reduce reaction risk
›Four-factor PCC
›Dose per INR and local protocol
›Class I recommendation for life-threatening bleeding reversal in many guidelines
›Dabigatran
›Idarucizumab
›5 g IV divided doses
›If life-threatening bleed confirmed
›Factor Xa inhibitors
›Andexanet alfa or PCC per availability and protocol
›Agent selection based on institutional policy
›Antiplatelet agents
›Platelet transfusion not routine without operative indication
›Neurosurgery guidance
›Seizure management
›Active seizure
›Lorazepam IV
›0.1 mg per kg IV
›Maximum 4 mg per dose
›Post-traumatic seizure prophylaxis
›Not routine for uncomplicated concussion
›Consider only with structural injury and specialist input
›Therapies not recommended routinely
›Corticosteroids for traumatic brain injury
›Not recommended due to harm signal in severe TBI trials
›Routine antibiotics for basilar skull fracture without infection
›Not recommended in most guidance without clear infection